Chronic Graft-Versus-Host Disease after allogeneic stem cell transplantation: Challenges in prevention, science, and supportive care

Journal of Supportive Oncology

Volumn 6, Issue 8, 2008, Pages 361-372

  Joseph, Richard W ^a,b,c   Couriel, Daniel R ^a,b,c   Komanduri, Krishna V ^a,b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b Tennessee Oncology Department   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ARTIFICIAL TEAR; BETAMETHASONE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOBETASOL; CYTOKINE; DEXAMETHASONE; FLUOCINONIDE; HEMOPOIETIC GROWTH FACTOR; HLA ANTIGEN; HYDROCORTISONE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; IRON CHELATING AGENT; MACROLIDE; METHYLPREDNISOLONE; OXYGEN; PENICILLIN G; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RITUXIMAB; SUNSCREEN; T LYMPHOCYTE ANTIGEN; TACROLIMUS; TRIAMCINOLONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVOR; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; CYTOKINE RELEASE; DISEASE CLASSIFICATION; DRUG DOSE TITRATION; EYE DISEASE; GASTROINTESTINAL DISEASE; GRAFT RECIPIENT; HEALTH CARE PLANNING; HEALTH PRACTITIONER; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HOSPITAL PATIENT; HUMAN; INCIDENCE; INFECTION; LIVER DISEASE; LONG TERM CARE; LUNG DISEASE; MOUTH DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PROTECTIVE CLOTHING; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SKIN DISEASE; SUPPORT GROUP; SURVIVAL TIME; VAGINA DISEASE; ALLOTRANSPLANTATION; CHRONIC DISEASE; CLASSIFICATION; GRAFT VERSUS HOST REACTION; RISK FACTOR; STEM CELL TRANSPLANTATION;

CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; INCIDENCE; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 59449106532     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Appelbaum FR. Hematopoietic-cell transplantation at 50. n Engl J Med 2007;357:1472-1475.
2. Champlin R, Khouri I, Kornblau S, et al. Allogeneic hematopoietic transplantation as adoptive immunotherapy: induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin north Am 1999;13:1041-1057.
3. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-637.
4. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Cin Oncol 1998;16:2817-2824.
5. Komanduri KV, Couriel D, Champlin RE. Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis. Biol Blood Marrow Transplant 2006;12(1 suppl 2):1-6.
6. Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004;101:1936-1946.
7. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007;7:340-352.
8. Teshima T, Wynn TA, Soiffer RJ, Matsuoka K, Martin PJ. Chronic graft-versus-host disease: how can we release Prometheus? Biol Blood Marrow Transplant 2008;14:142-150.
9. Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ. Transplantation's greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007;13(1 suppl 1):2-10.
10. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981;57:267-276.
11. Antin JH, Chen AR, Couriel DR, Ho VT, nash RA, Weisdorf D. novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2004;10:655-668.
12. Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957;257:491-496.
13. Kolb H, Sale GE, Lerner KG, Storb R, Thomas ED. Pathology of acute graft-versus-host disease in the dog: an autopsy study of ninety-five dogs. Am J Pathol 1979;96:581-594.
14. Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975;292:832-843.
15. Thomas ED, Buckner CD, Clift RA, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979;301:597-599.
16. Martin WJ, Miller JF. Cell to cell interaction in the immune response. IV. Site of action of antilymphocyte globulin. J Exp Med 1968;128:855874.
17. Cain WA, Cooper MD, Good RA. Cellular immune competence of spleen bursa and thymus cells. Nature 1968;217:87-89.
18. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;300:1068-1073.
19. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995;23:1553-1562.
20. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465.
21. Schmitz N, Eapen M, Horowitz MM, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006;108:4288-4290.
22. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983;98:461-466.
23. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I.Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956.
24. Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001;97:1219-1226.
25. Martin PJ, Weisdorf D, Przepiorka D, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 2006;12:491-505.
26. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006;12:375-396.
27. Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant 2006;12:126-137.
28. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667-674.
29. Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev 2003;17:187-194.
30. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285:412-415.
31. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004;10:987-992.
32. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396:690-695.
33. Poulin JF, Viswanathan MN, Harris JM, et al. Direct evidence for thymic function in adult humans. J Exp Med 1999;190:479-486.
34. Komanduri KV. Thymic function and allogeneic T-cell responses in stem-cell transplantation. Cytotherapy 2002;4:333-342.
35. Komanduri KV, St John LS, de Lima M, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T cell skewing. Blood 2007;110:4543-4551.
36. Muller-Hermelink HK, Sale GE, Borisch B, Storb R. Pathology of the thymus after allogeneic bone marrow transplantation in man: a histologic immunohistochemical study of 36 patients. Am J Pathol 1987;129:242-256.
37. Kong FK, Chen CL, Cooper MD. Reversible disruption of thymic function by steroid treatment. J Immunol 2002;168:6500-6505.
38. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006;108:756-762.
39. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003;9:505-511.
40. Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001;98:1695-1700.
41. Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002;100:48-51.
42. Artlett CM, Smith JB, Jimenez SA. new perspectives on the etiology of systemic sclerosis. Mol Med Today 1999;5:74-78.
43. Aractingi S, Chosidow O. Cutaneous graft-versus-host disease. Arch Dermatol 1998;134:602-612.
44. Kitajima T, Imamura S. Graft-versus-host reaction enhanced by ultraviolet radiation. Arch Dermatol Res 1993;285:499-501.
45. Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004;103:78-84.
46. Epstein O, Thomas HC, Sherlock S. Primary biliary cirrhosis is a dry gland syndrome with features of chronic graft-versus-host disease. Lancet 1980;1:1166-1168.
47. Fried RH, Murakami CS, Fisher LD, et al. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992;116:624-629.
48. Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood 2005;105:4200-4206.
49. Treister NS, Cook EF Jr, Antin J, Lee SJ, Soiffer R, Woo SB. Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008;14:110-115.
50. Redding SW, Callander NS, Haveman CW, Leonard DL. Treatment of oral chronic graft-versus-host disease with PUVA therapy: case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:183-187.
51. Nakamura S, Hiroki A, Shinohara M, et al. Oral involvement in chronic graft-versus-host disease after allogeneic bone marrow transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:556-563.
52. Franklin RM, Kenyon KR, Tutschka PJ, Saral R, Green WR, Santos GW. Ocular manifestations of graft-vs-host disease. Ophthalmology 1983;90:4-13.
53. Ralph DD, Springmeyer SC, Sullivan KM, Hackman RC, Storb R, Thomas ED. Rapidly progressive air-flow obstruction in marrow transplant recipients: possible association between obliterative bronchiolitis and chronic graft-versus-host disease. Am Rev Respir Dis 1984;129:641-644.
54. Rosenberg ME, Vercellotti GM, Snover DC, Hurd D, McGlave P. Bronchiolitis obliterans after bone marrow transplantation. Am J Hematol 1985;18:325-328.
55. Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003;168:208-214.
56. Chien JW, Madtes DK, Clark JG. Pulmonary function testing prior to hematopoietic stem cell transplantation. Bone Marrow Transplant 2005;35:429-435.
57. Bashoura L, Gupta S, Jain A, et al. Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008;41:63-67.
58. McDonald GB, Sullivan KM, Schuffler MD, Shulman HM, Thomas ED. Esophageal abnormalities in chronic graft-versus-host disease in humans. Gastroenterology 1981;80:914-921.
59. Weisdorf DJ, Snover DC, Haake R, et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990;76:624-629.
60. McDonald GB, Shulman HM, Sullivan KM, Spencer GD. Intestinal and hepatic complications of human bone marrow transplantation: part I. Gastroenterology 1986;90:460-477.
61. Ozdemir E, Saliba RM, Champlin RE, et al. Risk factors associated with late cyto-megalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007;40:125-136.
62. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001;33:139-144.
63. Nagano I, Takao T, Nanamiya W, et al. Differential effects of one and repeated endotoxin treatment on pituitary adrenocortical hormones in the mouse: role of interleukin-1 and tumor necrosis factor-alpha. Neuroimmunomodulation 1999;6:284-292.
64. Masumoto A, Sasao T, Yoshiba F, et al. Hypereosinophilia after allogeneic bone marrow transplantation: a possible role of IL-5 overproduction by donor T-cells chronic GVHD [in Japanese]. Rinsho Ketsueki 1997;38:234-236.
65. Lee SJ, Vogelsang G, Gilman A, et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant 2002;8:32-39.
66. Bolger GB, Sullivan KM, Spence AM, et al. Myasthenia gravis after allogeneic bone marrow transplantation: relationship to chronic graft-versus-host disease. Neurology 1986;36:1087-1091.
67. Greenspan A, Deeg HJ, Cottler-Fox M, Sirdofski M, Spitzer TR, Kattah J. Incapacitating peripheral neuropathy as a manifestation of chronic graft-versus-host disease. Bone Marrow Transplant 1990;5:349-352.
68. Parker P, Chao NJ, Ben-Ezra J, et al. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine (Baltimore) 1996;75:279-285.
69. Couriel D, Hosing C, Saliba R, et al. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Biol Blood Marrow Transplant 2006;12(1 suppl 2):37-40.
70. Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006;107:3074-3080.
71. Sakaguchi S, Sakaguchi n, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
72. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002;99:3493-3499.
73. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002;196:389-399.
74. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-1150.
75. Levings MK, Sangregorio R, Roncarolo MG. Human CD25+CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001;193:1295-1302.
76. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4(+)CD25(+)Foxp3(+) regulatory T lymphocytes. Nat Med 2008;14:88-92.
77. Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008;111:453-462.
78. Solomon SR, Mielke S, Savani BN, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005;106:1123-1129.
79. Amrolia PJ, Muccioli-Casadei G, Yvon E, et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 2003;102:2292-2299.
80. Martins SL, St. John LS, Champlin RE, et al. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 2004;104:3429-3436.
81. Gregori S, Bacchetta R, Hauben E, Battaglia M, Roncarolo MG. Regulatory T cells: prospective for clinical application in hematopoietic stem cell transplantation. Curr Opin Hematol 2005;12:451-456.